Capricor Therapeutics Investors May Join Class Action Lawsuit
Capricor Therapeutics Faces Legal Challenges
Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself in troubled waters as several shareholders have lost significant money on their investments. This situation has prompted investors to consider a class action lawsuit against the company. Accusations relate to misleading information presented about their promising drug candidate called deramiocel, designed to treat cardiomyopathy linked with Duchenne muscular dystrophy (DMD).
Understanding the Class Period
Investors who purchased shares of Capricor between October 9, 2024, and July 10, 2025, may be eligible to participate in this lawsuit. It’s crucial for those affected to act quickly, as the deadline for filing is approaching.
Allegations Against Capricor
The allegations claim that Capricor misled investors with optimistic projections regarding their drug’s approval process. Specifically, the company suggested that it would be successful in obtaining a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). However, it subsequently became clear that Capricor had been less than forthcoming about the results of its Phase 2 HOPE-2 trial involving deramiocel, including safety and efficacy data.
On July 11, 2025, the situation took a further downturn as Capricor announced it had received a Complete Response Letter (CRL) from the FDA. This letter detailed the FDA's concerns regarding the inadequate evidence of the drug's effectiveness and highlighted the need for more clinical data before approval. In a staggering impact on investors, the company's stock plummeted from $11.40 per share on July 10 to $7.64 per share the following day, marking a significant loss for shareholders.
Next Steps for Affected Shareholders
For those invested in Capricor, it is crucial to understand the next steps. By registering as shareholders who bought shares during the class period, they will be included in a portfolio monitoring system. This system will provide updates throughout the legal proceedings. Importantly, there is no cost or obligation for participation.
The Gross Law Firm's Role
The Gross Law Firm is spearheading this class action endeavor and has positioned itself as a defender of investor rights. Their mission is to safeguard shareholders from deceptive and illicit business tactics. With a reputation for fighting on behalf of investors, the firm stands ready to assist those who have suffered financial damages due to misleading business practices. They aim to hold corporations accountable for their actions while promoting ethical behavior in the marketplace.
Contact Information and Legal Help
Affected investors are encouraged to reach out to The Gross Law Firm for further assistance. The firm’s office is located at 15 West 38th Street, 12th floor, New York, NY 10018, and can be contacted by phone at (646) 453-8903. The firm's objective is to ensure transparent communication and support for all investors involved.
Frequently Asked Questions
What is the class action about?
The class action addresses potential misleading statements made by Capricor Therapeutics regarding their drug deramiocel and its FDA approval process.
Who can join the class action?
Shareholders who purchased shares of Capricor from October 9, 2024, to July 10, 2025, may be eligible to join the class action.
How do I register for the class action?
Interested shareholders should register their information promptly to ensure they are included in the legal proceedings.
What happens after I register?
Once you register, you will have access to ongoing updates related to the case and its developments.
Is there any cost to participate?
No, there is no cost or obligation to participate in the class action.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.